Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07489534CT.gov Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction | — | Recruiting | — | — | — |
NCT07106736CT.gov MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT07106710CT.gov ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT07106684CT.gov ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia | — | Recruiting | — | — | — |
NCT06732232CT.gov A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07139509CT.gov Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06581640CT.gov Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05740891CT.gov AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT05712083CT.gov A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT05150522CT.gov B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | — | Unknown | — | — | — |
Show 10 more trialsShow fewer
NCT04447573CT.gov Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04626752CT.gov CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04272151CT.gov Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT03931421CT.gov B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT04271644CT.gov BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | — | Recruiting | — | — | — |
NCT03767751CT.gov A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT03706547CT.gov Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | — | Unknown | — | — | — |
NCT04650724CT.gov Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor | — | Completed | — | — | — |
NCT03661554CT.gov BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT03322735CT.gov Study of BCMA CAR-T in Multiple Myeloma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bcma Car-T Cells (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | B · 58 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Bcma Car-T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | CCC · 53 |
| Plasma Cell Neoplasm | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bcma Car-T Cells in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bcma-car-t-cells-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →